The decrease in obesity-related features through GLP-1 treatment was linked to positive effects on fasting glucose, insulin sensitivity (homeostatic model assessment for insulin resistance – HOMA-IR), metabolic syndrome and hormonal markers (testosterone, androstenedione and SHBG), but some studies were unable to demonstrate clinical endocrine benefits (menstrual frequency) (54, 56, 57). This evidence concerns the gene GLP1R and obesity disorder.